13.92 USD
▲+0.11+4.11%
盘后 13.37 0.00%
2026-08-03
市值
$1.17B
市盈率
—
EPS
-0.55
股息率
—
52 周区间
4.05 – 26.95
成交量
766.89K
Beta
0.82
目标价
33.14
52W 低 4.0552W 高 26.95
价格走势
公司简介
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferat...